A76109
3-Amino-1-propanesulfonic acid
97%
Synonym(s):
3APS, Homotaurine, Tramiprosate
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Recommended Products
Quality Level
Assay
97%
form
solid
mp
293 °C (dec.) (lit.)
SMILES string
NCCCS(O)(=O)=O
InChI
1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)
InChI key
SNKZJIOFVMKAOJ-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
Application
Important gabamimetic agent-evokes neurological responses similar to those elicited by γ-aminobutyric acid (GABA).
Storage Class Code
13 - Non Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
The journal of nutrition, health & aging, 13(9), 808-812 (2009-10-09)
Tramiprosate (homotaurine, ALZHEMEDTM) was recently investigated for its efficacy, safety and disease-modification effects in a Phase III clinical study in mild to moderate Alzheimer's disease (AD) patients (the Alphase study). The primary cognitive endpoint measure of that study was the
Journal of biomedical science, 8(1), 96-103 (2001-02-15)
Acamprosate (AC), N-acetyl-homotaurine, has recently been introduced for treating alcohol craving and reducing relapses in weaned alcoholics. AC may exert its action through the taurine system rather than the glutamatergic or GABAergic system. This conclusion is based on the observations
The journal of nutrition, health & aging, 13(6), 550-557 (2009-06-19)
The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer's disease (AD), the Alphase study. Disease-modification was assessed using longitudinal volumetric MRI (vMRI) measurements of
Journal of pharmaceutical and biomedical analysis, 55(2), 282-287 (2011-02-18)
Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits composed of amyloid β (Aβ) protein. A simple and rapid method using HPLC with fluorescence detector was developed and validated for determination of tramiprosate in rat plasma. Pre-column derivatization of
Neurology, 67(10), 1757-1763 (2006-11-04)
As a potential disease-modifying treatment for Alzheimer disease (AD), 3-amino-1-propanesulfonic acid (3APS) is a compound that binds to amyloid beta (Abeta), a toxic protein known to aggregate, leading to amyloid plaque deposition in the brain. We assessed the safety, tolerability
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service